Views: 0 Author: Robert Chen Publish Time: 2026-05-13 Origin: Jinan Chensheng Medical Technology Co., Ltd.
If you're selling medical devices containing silicone components, you're probably dealing with—or will need to deal with—multiple regulatory frameworks. The FDA, EU MDR, and China's NMPA each have their own requirements, procedures, and philosophies.
Let's cut through the confusion and give you a practical comparison of how these three major regulatory systems handle silicone medical devices.
Before diving into specifics, here's an overview of how these systems differ in their approach:
FDA (United States): Performance-based regulation with post-market emphasis. The FDA sets requirements but relies heavily on industry self-certification and post-market surveillance.
CE Marking / EU MDR (European Union): Risk-based regulation with pre-market scrutiny. The MDR requires comprehensive technical documentation and ongoing clinical evidence.
NMPA (China): Increasingly harmonizing with international standards but maintains distinct procedures, testing requirements, and local considerations.
The FDA classifies devices into three classes based on risk:
Class I (Low Risk): General controls, most are exempt from premarket review
Class II (Moderate Risk): General controls plus special controls, typically requires 510(k)
Class III (High Risk): Premarket approval (PMA) required
Most silicone components for medical devices fall into Class I or II, meaning 510(k) clearance is often the pathway. However, devices with prolonged tissue contact or critical functionality may be Class III.
For most silicone devices, you'll need to submit a 510(k) demonstrating "substantial equivalence" to a legally marketed predicate device. This requires:
Device Description: Comprehensive description of the silicone device, materials, dimensions, and manufacturing process.
Predicate Comparison: Comparison to a legally marketed device showing similar intended use and technological characteristics.
Biocompatibility Documentation: Per ISO 10993 series, with testing appropriate to tissue contact duration and type.
Manufacturing Information: Brief description of manufacturing processes and quality system overview.
Labeling: Complete labeling with intended use statements.
The FDA aims to review 510(k)s within 90 days, but actual timelines often run 6-12 months or longer depending on submission quality and FDA workload.
Under 21 CFR Part 820 (Quality System Regulation, or QSR), manufacturers must establish and maintain quality systems covering:
Design controls
Production and process controls
Corrective and preventive action (CAPA)
Document and records control
Complaint handling
The FDA increasingly expects compliance aligned with ISO 13485, even though the regulations differ somewhat in specifics.
Predicate Selection: Finding an appropriate predicate device can be challenging for novel silicone applications. A good regulatory strategy considers predicate availability early.
Biocompatibility Testing: The FDA strongly prefers direct testing per ISO 10993 rather than literature citations. Plan for 3-6 months of biocompatibility testing.
Manufacturing Changes: Any significant changes to silicone formulation, manufacturing process, or supplier require review. Establish change control procedures.
Since May 2021, all medical devices sold in the EU must comply with the Medical Device Regulation (MDR) 2017/745, which replaced the older Medical Device Directive (MDD). The MDR significantly increased requirements, especially for:
Technical Documentation: Comprehensive documentation covering device description, design and manufacturing information, risk analysis, clinical evaluation, and post-market surveillance plans.
Clinical Evidence: Stronger requirements for clinical data to support safety and performance claims. Many devices previously certified under MDD now face gaps requiring additional clinical evidence.
Post-Market Surveillance: Ongoing requirements to collect and analyze post-market data, including periodic safety update reports (PSURs).
The MDR uses classification rules that often result in higher classifications than the old MDD. Most silicone medical devices fall into:
Class I: Low risk, self-certification possible (but must register)
Class IIa: Moderate risk, requires notified body assessment
Class IIb: Higher moderate risk, requires notified body assessment
Class III: High risk, requires intensive notified body review
For most silicone devices requiring notified body involvement, you'll follow either:
Annex IX (Quality management and clinical evaluation): Assessment of QMS and clinical evaluation documentation.
Annex XI (Production quality assurance): Assessment of production quality assurance processes.
The choice depends on device classification and manufacturer preferences.
MDR requires compliance with ISO 10993 for biocompatibility, similar to FDA requirements. However, MDR also requires:
Chemical Characterization: Detailed chemical analysis of all constituents that could migrate from the silicone material.
Risk Assessment: Systematic evaluation of identified substances for potential harm.
Re-evaluation Triggers: Changes in material composition or processing require re-evaluation of biocompatibility.
Notified Body Capacity: The transition to MDR revealed significant bottlenecks in notified body capacity. Lead times for new certifications have stretched considerably.
Clinical Evidence Requirements: The MDR's emphasis on clinical evidence has caught many manufacturers unprepared, especially those who relied on equivalence to support their CE marking under MDD.
EUDAMED Registration: The new European database requires registration and ongoing reporting, with phased implementation.
China's NMPA (formerly CFDA) has been modernizing its regulatory framework, moving toward greater harmonization with international standards while maintaining distinct requirements.
The revised Medical Device Regulations (State Council Order 739) and associated registration procedures govern device approval in China.
NMPA uses a classification system with four classes:
Class I: Simple registration, local NMPA filing
Class II: Provincial-level registration with technical review
Class III: National-level registration with NMPA central review
Most silicone medical devices fall into Class II or III, requiring formal registration.
Class II Devices:
Compile Chinese-language technical documentation
Submit to provincial NMPA
Technical review and testing at designated laboratories
Approval and certificate issuance
Class III Devices:
Compile documentation per NMPA requirements
Submit to NMPA Center for Medical Device Evaluation
Technical review with potential expert panel review
Testing at NMPA-designated testing laboratories
On-site inspection of manufacturing facilities
Approval
Timelines vary significantly: Class II registration typically takes 12-18 months; Class III can take 2-3 years or longer.
Chinese Standards (YY/T): NMPA may require testing per specific Chinese standards, which may differ from ISO equivalents. These must be identified early in planning.
Testing Laboratory Requirements: Testing must be performed at NMPA-designated testing laboratories, not just any ISO/IEC 17025 accredited lab.
Manufacturing Site Inspection: For Class III devices, NMPA typically conducts on-site inspections of the manufacturing facility as part of registration.
Local Representative: Foreign manufacturers must designate a Chinese agent to handle regulatory affairs.
Chinese Language Documentation: All submitted documentation must be in Chinese (or include certified Chinese translations).
NMPA has been working to:
Streamline registration procedures
Accept foreign clinical data more readily
Establish mutual recognition agreements with other regulatory bodies
Implement unique device identification (UDI) requirements
Aspect | FDA (US) | CE Marking (EU) | NMPA (China) |
Classification Basis | Risk + intended use | Risk + duration of contact | Risk + intended use |
Premarket Review | 510(k) or PMA | Notified body review | Technical review + testing |
Biocompatibility | ISO 10993 preferred | ISO 10993 required | ISO 10993 or YY/T equivalents |
Quality System | 21 CFR Part 820 | ISO 13485 | ISO 13485 + NMPA requirements |
Timeline (typical) | 6-12 months | 9-18 months | 12-24+ months |
Clinical Data | Variable by device type | Extensive required | Increasingly required |
Foreign Manufacturer | US Agent required | Authorized Representative | Chinese Agent mandatory |
Given that requirements overlap significantly, design your regulatory strategy around the most demanding market (often EU MDR for comprehensive documentation). Building to MDR standards typically means FDA and NMPA submissions are also achievable.
ISO 10993, ISO 13485, and related standards provide a common foundation recognized across all three regulatory systems. Invest in compliance with these standards early.
Biocompatibility testing typically requires 3-6 months. Build this into your project timeline and consider parallel testing across multiple endpoints to accelerate the process.
Documentation prepared for one regulatory submission should be structured to support others. A well-organized technical file can often be adapted for multiple markets.
Your silicone component supplier should understand regulatory requirements across markets. At Chensheng Medical, we support customers pursuing FDA, CE, and NMPA registration with:
Complete biocompatibility documentation
Quality system certifications (ISO 13485)
Technical documentation packages
Manufacturing process validation
Change notification and control
Regulatory submissions in multiple jurisdictions benefit from professional support. Regulatory affairs consultants with specific market expertise can navigate nuances and avoid costly delays.
Underestimating Timeline: All three systems take longer than initial expectations suggest. Build in buffer time.
Inadequate Biocompatibility Documentation: Don't assume past testing is sufficient. Tissue contact type and duration must be re-evaluated for each device.
Change Control Neglect: Even approved devices require change control procedures. A formulation tweak by your silicone supplier can trigger regulatory obligations.
Incomplete Labeling: Each market has specific labeling requirements. "FDA cleared" labeling is not "CE marked" labeling.
Documentation Language: All three systems require documentation in their official language (or certified translations for NMPA). Plan for translation costs and timelines.
Navigating FDA, CE, and NMPA requirements for silicone medical devices requires careful planning, substantial documentation, and ongoing attention to regulatory compliance. But with the right approach and qualified partners, multi-market access is achievable.
Focus on building a strong quality system foundation, invest in comprehensive biocompatibility testing, and maintain rigorous change control procedures. These fundamentals serve you well regardless of which regulatory systems you're targeting.
Need help understanding how these requirements apply to your specific silicone medical device? We're happy to discuss your regulatory strategy and how we can support your market access goals.
Navigating the complexities of FDA, CE, and NMPA regulations can be challenging. At Chensheng Medical, we provide expert guidance to help you understand and meet these requirements effectively.
Contact Us to discuss your regulatory strategy and learn how we can support your market access goals.
You can also explore more insights on our Blog.
Author: Robert Chen, Director of Regulatory Affairs at Chensheng Medical
Robert has guided over 200 medical device products through FDA, CE, and international regulatory approvals, specializing in silicone-based devices and combination products.
